Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTO0FDJ)

• DTT Name: Cyclin-dependent kinase 6 (CDK6) DTT Info
• Gene Name: CDK6

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[1]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[2]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[3]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[4]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[5]

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[6]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[7]
FCN-437	DMQ8VUW	Breast cancer	2C60-2C65	Phase 1/2	[8]
GLR2007	DM7DWLY	Glioblastoma of brain	2A00.00	Phase 1/2	[9]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[10]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
G1T28-1	DML028U	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
RGT-419B	DMD2MND	Breast cancer	2C60-2C65	Phase 1	[12]

7 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoquinoline 1,3-dione derivative 1	DMIYUAN	N. A.	N. A.	Patented	[13]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[13]
PMID25726713-Compound-47	DMXE5KM	N. A.	N. A.	Patented	[14]
PMID25726713-Compound-48	DMSIOUA	N. A.	N. A.	Patented	[14]
PMID25726713-Compound-49	DM2CT4G	N. A.	N. A.	Patented	[14]
PMID25726713-Compound-50	DM3BDFV	N. A.	N. A.	Patented	[14]
PMID25726713-Compound-51	DMF0OW4	N. A.	N. A.	Patented	[14]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INOC-005	DMBQGZ9	Solid tumour/cancer	2A00-2F9Z	Preclinical	[15]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CYC-103	DM17NYA	Solid tumour/cancer	2A00-2F9Z	Terminated	[16]
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[17]

9 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[18]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[18]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[19]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[18]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[20]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[20]
Deschloroflavopiridol	DMQER8D	Discovery agent	N.A.	Investigative	[17]
Fascaplysin	DMG5OZP	Discovery agent	N.A.	Investigative	[17]
RGB-286147	DMP08BY	Discovery agent	N.A.	Investigative	[21]

References

• [1] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
• [9] Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
• [10] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [11] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [12] Clinical pipeline report, company report or official report of Regor Therapeutics
• [13] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [14] Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
• [15] What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15.
• [16] WO patent application no. 2007,0898,78, Sutures and anti-scarring agents.
• [17] Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
• [18] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [19] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [20] Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43.
• [21] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.